Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues Earnings Results, Misses Expectations By $0.47 EPS

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced its quarterly earnings results on Monday. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47), FiscalAI reports. Jazz Pharmaceuticals had a return on equity of 35.03% and a net margin of 20.45%.The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. During the same quarter in the prior year, the business earned ($8.25) EPS. The firm’s revenue for the quarter was up 15.5% on a year-over-year basis.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

• Record revenue of $1.21 billion rose 16% year over year, prompting Jazz to raise 2026 revenue guidance to $4.60 billion–$4.75 billion. Adjusted EPS was $5.71, while first-half operating cash flow reached $824 million.
• XYWAV sales increased 13% to $471 million, with approximately 525 net patient additions and limited uptake of high-sodium generics. Jazz now expects double-digit XYWAV growth in 2026 and raised rare-sleep revenue guidance to $2.025 billion–$2.125 billion.
• Epidiolex sales grew 16% to $292 million on strong underlying demand, particularly among adult and long-term-care patients. Jazz is pursuing a capsule formulation and several clinical trials to expand usage across additional treatment-resistant seizure populations.
• Jazz expressed high confidence in zanidatamab’s approval for first-line HER2-positive metastatic GEA by the August 25 PDUFA date and said it is prepared for launch. The company highlighted median overall survival of 26.4 months in the combination arm and expects additional doublet overall-survival data in the third quarter.
• Zepzelca sales rose 42% to $106 million, driven by first-line maintenance adoption, but Jazz plans to submit a labeling supplement removing the second-line indication after the LAGOON results. Management expects the historical second-line business to continue eroding, with a possible acceleration following the label change.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $264.30 on Wednesday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The company has a market capitalization of $16.60 billion, a P/E ratio of -13,220.89, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. The company’s 50 day moving average price is $239.98 and its two-hundred day moving average price is $207.93. Jazz Pharmaceuticals has a 52 week low of $105.00 and a 52 week high of $262.00.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported second-quarter revenue of approximately $1.21 billion, up 15.5% year over year and above the $1.11 billion analyst consensus. Xywav revenue increased 13%, Epidiolex revenue rose 16%, and the company added 525 net Xywav patients during the quarter. Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its 2026 revenue outlook to roughly $4.60 billion-$4.75 billion, above Wall Street expectations near $4.5 billion. The stronger forecast reflects demand across the neuroscience and oncology portfolios, including resilience in the oxybate franchise despite generic Xyrem competition. Jazz forecasts 2026 revenue
• Positive Sentiment: Investors are looking ahead to Ziihera’s potential FDA approval for first-line HER2-positive gastroesophageal adenocarcinoma, with a decision expected August 25. Approval could open a sizable new revenue opportunity and support faster sequential growth. Jazz Pharmaceuticals’ Re-Rating Story Has Legs
• Positive Sentiment: Several analysts raised their price targets and maintained bullish ratings: Needham increased its target to $292, while Morgan Stanley and Robert W. Baird raised theirs to $280. JPMorgan lifted its target to $276 and rated the shares Overweight.
• Neutral Sentiment: Second-quarter adjusted EPS was $5.71, below estimates ranging from $6.04 to $6.18, although it improved substantially from a loss of $8.25 in the prior-year period. Jazz Pharmaceuticals earnings report
• Negative Sentiment: Jazz plans to withdraw Zepzelca’s FDA application for second-line small-cell lung cancer, removing that indication from its near-term commercial opportunity and underscoring competitive or regulatory challenges for the treatment. Jazz to withdraw Zepzelca with FDA

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total transaction of $278,196.00. Following the completion of the sale, the executive vice president owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total value of $1,442,820.00. Following the transaction, the director owned 366,682 shares of the company’s stock, valued at approximately $88,176,020.54. This trade represents a 1.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,098 shares of company stock valued at $3,131,906. 4.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of JAZZ. Strategic Investment Advisors MI acquired a new position in Jazz Pharmaceuticals during the second quarter worth $233,000. Quantessence Capital LLC acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $212,000. Graham Capital Management L.P. acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $206,000. UMB Bank n.a. lifted its position in Jazz Pharmaceuticals by 12.6% during the 4th quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 81 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Jazz Pharmaceuticals by 53.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 902 shares of the specialty pharmaceutical company’s stock worth $96,000 after buying an additional 313 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on JAZZ shares. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. Stifel Nicolaus set a $275.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday. Raymond James Financial reaffirmed an “outperform” rating and issued a $239.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Leerink Partners increased their price target on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Finally, Canaccord Genuity Group initiated coverage on Jazz Pharmaceuticals in a research note on Thursday, July 16th. They set a “buy” rating and a $290.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $272.74.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.